Navigation Links
VaxGen Issues Rebuttal to MedCap Letter
Date:3/25/2008

MedCap press releases contain false and misleading information

SOUTH SAN FRANCISCO, Calif., March 25 /PRNewswire-FirstCall/-- VaxGen Inc. (OTC Bulletin Board: VXGN.OB)
(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

Dear Stockholders,

On March 19th, MedCap Management & Research, LLC, a stockholder in VaxGen, issued a press release entitled "MedCap Urges Vote Against Proposed VaxGen Merger with Raven biotechnologies". We believe this release, one of MedCap's increasingly personal attacks on VaxGen, contains false and misleading information.

MedCap presents a financial analysis which is both incorrect and shallow, selectively extracting information from VaxGen's 2007 financial statements and misrepresenting its meaning. MedCap implies poor stewardship by the Company's Board and executives by substantially inflating and mischaracterizing expenditures. In fact, VaxGen's net cash used in operating activities was reduced by nearly 65% for 2007 versus 2006 and staffing was reduced by 89%; hardly a record of inaction or mismanagement by management and the Board. Likewise, MedCap's liquidation analysis shows a profound misunderstanding of the liquidation process, and fails to distinguish between the radically different outcomes for debt versus equity holders in a liquidation. Both of these analyses are addressed in more detail in the addendum to this letter.

Because professional investment analysts would typically draw a distinction between cash burn and P&L expenses, and understand the implications of a liquidation, MedCap's flawed assertions could easily mislead stockholders of VaxGen. This situation is further exacerbated by MedCap's inaccurate and highly selective use of third party references.

MedCap draws on the views of two third parties to bolster its arguments: Sharon Seiler, Ph.D., the Senior Biotechnology
'/>"/>

SOURCE VaxGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
3. VaxGen Files First Quarter 2007 Financials
4. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
5. VaxGen Files Last Outstanding Periodic Report With SEC
6. VaxGen Addresses MPM Claims in Letter to Stockholders
7. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
8. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
9. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
10. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
11. VaxGen Reports Financial Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 02, 2015 , ... Sleepless nights will become obsolete as Luzi ... its Indiegogo campaign on June 23. Sound sleepers and the sleep deprived both will ... to use, while the integration of the Bluetooth speaker, alarm clock and ability to ...
(Date:7/1/2015)... and PARIS , ... AgBiome, and Genective, key developer of biotech crops, ... discovery of new generations of insect control traits. ... control to counter the realities of advancing insect ... aligning AgBiome,s unique insect control technology with Genective,s ...
(Date:7/1/2015)... AURORA, Colo. and BANGALORE, India ... a global genomic profiling company that uses next generation ... appointment of Scott A. Storrer as chief ... and CEO, he will be responsible for all strategy, ... Vijay Chandru , who has served as Strand,s chairman ...
(Date:7/1/2015)... Isagenix International, a leading global health and ... Silver, and three Bronze Stevie® Awards at the 2015 ... Chicago this month.The American Business Awards ... in the U.S. "Winning is a ... leaders, cultivating talent, creating a unified team, and crafting ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3AgBiome and Genective collaborate to create novel insect-resistant crops 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3
... 28, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... extension study (MOR-100) in which patients have continued treatment on ... the initial Phase 1/2 study of GALNS (MOR-002) were continued ... MOR-100 study, patients were treated at a 2.0 mg/kg/week dose ...
... AllograftPossibilities.org has rapidly grown into the premier ... on the web. Although it has the same life-saving ... still lesser understood by the general public. The nonprofit ... of bone and soft-tissue allografts for use in surgical ...
... SAN DIEGO, July 28, 2011 Verenium Corporation (NASDAQ: ... and commercialization of high-performance industrial enzyme solutions, today announced ... of its 5.5% Notes and approximately $3 million in ... are very pleased to have taken another important step ...
Cached Biology Technology:BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 2BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 3BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 4BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 5BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 6AllograftPossibilities.org Meets Unmet Need for Consumer-Oriented Information on Tissue Donation, Transplantation on the Internet 2AllograftPossibilities.org Meets Unmet Need for Consumer-Oriented Information on Tissue Donation, Transplantation on the Internet 3Verenium Announces Debt Repurchase 2Verenium Announces Debt Repurchase 3
(Date:6/23/2015)... Fla. , June 23, 2015 /PRNewswire/ ... management and authentication solutions, today announced enhanced functionality ... multi-factor authentication solution.  The enhancements build on ... of the DigitalPersona Altus platform and provide ... compatibility. In today,s environment of ...
(Date:6/17/2015)... , June 17, 2015 QIAGEN ... launched new Investigator ® STR assay kits for analysis ... United States . The new genetic fingerprint kits provide ... (short tandem repeats or STRs) for DNA matching. They incorporate ... of DNA in each sample, a novel QIAGEN technology that ...
(Date:6/16/2015)... 16, 2015  With the increasing number and severity ... top concern. The recent compromise of Federal employee ... strong authentication within government agencies. HYPR Corp. ... password (OTP) authenticator, has been submitted for testing and ... 3 validation for tamper proofing. The ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... (CHICAGO - Sept. 30, 2009) U.S. Environmental Protection Agency,s ... of a dioxin exposure study conducted by the University ... the study was conducted well and provided useful, scientifically ... to help EPA fully evaluate human exposure to levels ...
... KINSTON, N.C., Oct. 1 Spatial Integrated Systems, ... integration of solutions incorporating next-generation digital 3D data ... United States patent application has been published for ... 3-dimensional image rendering" under Publication No. US2009/0169095A1. , ...
... University of Warwick and Rothamsted Research have been awarded ... (BBSRC) in partnership with Syngenta, to research the decline ... have fallen by 10-15% over the last 2 years; ... 30% for 2008. Since the declines were first reported ...
Cached Biology News:EPA reviews Univ. of Michigan dioxin study 2Spatial Integrated Systems, Inc. Files Patent Application 2£1 million award to address honeybee decline 2£1 million award to address honeybee decline 3